FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto ® in routine clinical practice

A report from the U.S. Food and Drug Administration (FDA) published in Pharmacoepidemiology & Drug Safety confirms the safety profile and effectiveness of Xarelto® (rivaroxaban) in people with atrial fibrillation (AF). The study is based on electronic healthcare data within the Mini-Sentinel safety programme in the US, reporting data on a large real-world population of over 115,000 people prescribed rivaroxaban or warfarin.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news